Company news

Hemostemix Inc news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Hemostemix Announces Its Intellectual Property is Back Home

May 10, 2022

Hemostemix Announces Closing of $2,750,000

April 25, 2022

Hemostemix Inc. Announces Intellectual Property Due Diligence and Data Audit Completed

April 12, 2022

Hemostemix Announces Settlement Agreement

March 23, 2022

Hemostemix: Interest Payment on Convertible Debenture

March 3, 2022

Hemostemix Announces $2,750,000 Convertible Debenture

March 2, 2022

Hemostemix Announces Stock Options Grant

March 1, 2022

Your Fountain of Youth Trademarked by Hemostemix

February 14, 2022

Hemostemix Partners with My Next Health, Obtains USD $150,000 Subscription at CAD $0.25 Per Unit, and Incorporates Functional Genomics

January 21, 2022

Hemostemix to Combine ACP-01 with Dr. James Shapiro's Islet Cells to Treat Type 1 Diabetes

January 11, 2022

Virtual Conference for Life Sciences Companies Broadcast Live December 16th

December 14, 2021

Hemostemix Announces Soft Lock of Database as Source Document Verification Completed

December 9, 2021

Hemostemix Confirms OTCQB Listing

October 28, 2021

Hemostemix Confirms OTCQB Application is Filed

October 19, 2021

Hemostemix Announces Dr. Fraser C. Henderson Sr., MD, as Chief Medical Officer

October 14, 2021

Hemostemix Announces the Second Stem Cell Recipient Interview: One Week to No Chest Pain

October 4, 2021

Hemostemix Announces Closing of First Tranche of Unit Private Placement

September 21, 2021

Hemostemix Announces the First of a Series of 2021 Video Interviews with ACP-01 Recipients: What the Successful Compassionate Treatment of Ischemic Cardiomyopathy Looks Like After 13 Years

September 14, 2021

Hemostemix Announces Five Million Unit Private Placement

September 8, 2021

Hemostemix Provides Update of Phase II Clinical Trial, 9th Circuit Court Decision Including Cost Award and its Annual General Meeting Results

July 6, 2021

Hemostemix Announces Warrant Repricing and Extension

July 5, 2021

Peter Lacey Increases His Investment in Hemostemix Inc.

June 21, 2021

Hemostemix Announces the Closing of a $2,500,000 Convertible Debenture

June 11, 2021

Hemostemix Announces that, Due to the COVID-19 Pandemic, the Annual and Special Meeting Will Only Be Held via Zoom and Shareholders are Requested to Follow the Meeting Instructions Mailed to the Shareholders of Record

May 31, 2021

Hemostemix Announces the TSX Venture's Preliminary Approval of the Closing of a $2,500,000 Convertible Debenture at $0.40 per Unit and Corporate Update

May 29, 2021

Hemostemix to Present at the Emerging Growth Conference

May 25, 2021

Hemostemix Announces Closing of Unit Private Placement

May 10, 2021

Hemostemix Provides a Clinical Trial Update and Announces the Release and Filing of 2020 Year-end Audited Financial Statements and Management Discussion and Analysis

April 30, 2021

Hemostemix Reprices and Amends the Terms of Its Unit Offering and Debenture Offering

April 26, 2021

Hemostemix Announces Completion of Phase II Clinical Trial Subject Follow Up and HMTXF Up-list

April 23, 2021

Hemostemix Announces a $2,500,000 Lead Order and its Clinical Trial and Litigation Updates

April 9, 2021

Hemostemix Announces It Is Trading on the Frankfurt Stock Exchange and It Has Retained HE Capital Markets Ltd.

April 8, 2021

Hemostemix Announces Clinical Trial Update and Contract with GlobeX Data to Encrypt its Communications with Regulatory Authorities

March 18, 2021

Hemostemix Announces the Protocol First Contract and Warrant Repricing Approval

February 11, 2021

Hemostemix Announces HS 12 - 01 Clinical Trial Completion of Subjects' Follow-Up Visits at the End of March and Warrants Extended and Repriced

January 28, 2021

Hemostemix Announces the Bread Contract with the Department of Foreign Affairs, Trade & Development Canada

January 22, 2021

Hemostemix Announces Private Placement Update

December 29, 2020

Hemostemix Announces Corporate Update

December 23, 2020

Hemostemix Announces Closing of Existing Private Placement and Announces a New Private Placement

December 18, 2020

InvestmentPitch Media Video Discusses Hemostemix Successfully Obtaining all Clinical Trial Data and Announcement of $2.5 Million Unit Offering - Video Available on Investmentpitch.com

December 1, 2020

Hemostemix Files Its Unaudited Condensed Consolidated Interim Financial Statements and Management Discussion and Analysis for the Three Months Ended March 31, 2020

July 13, 2020

Hemostemix Files Its Audited Annual Financial Statements and Management Discussion and Analysis for the Period Ending December 31, 2019

July 10, 2020

Hemostemix Announces Closing of Private Placement

July 9, 2020

Delaware Court Grants An Order for the Expedited Briefing Schedule of Hemostemix's Injunction against Accudata Solutions, Inc. and Hemostemix is in Receipt of an Unsigned Report from Aspire Health Science

July 6, 2020

Hemostemix Filed an Injunction Against Accudata Solutions, Inc. for the Return of its Clinical Trial Midpoint Report and Data

July 3, 2020

Hemostemix Appeals Alberta Court's Service Ex Juris Decision

June 24, 2020

Hemostemix Announces $700,000 Non Broker Private Placement, Update on its Proceedings against Aspire Health Science, LLC

June 19, 2020

Hemostemix Announces Delay in Filing of Annual Financial Statements and Application for Management Cease Trade Order

June 16, 2020

Hemostemix Announces Aspire Health Science, LLC Has No Right to Manufacture or to Sublicense Hemostemix's Intellectual Property

June 8, 2020

Hemostemix Announces Dr. Mary Argent-Katwala as Its Clinical Trial Manager

June 3, 2020

← Newer news releases · Older news releases →

Decks